This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Medgenics Appoints Dr. Marvin Garovoy As Chief Medical Officer

Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the developer of Biopump™, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, is pleased to announce the appointment of Marvin Garovoy, M.D. as Chief Medical Officer. Dr. Garovoy is a transplant nephrologist, biotechnology executive and former university professor with experience in all stages of clinical development.

“While serving as Acting Chief Medical Officer since January 2012, Dr. Garovoy has helped Medgenics achieve a number of important clinical and corporate milestones,” stated Andrew L. Pearlman, Ph.D., President and Chief Executive Officer of Medgenics. “Dr. Garovoy’s vast experience and skillset will be a considerable asset as we initiate several new clinical trials through the end of 2012 in the U.S. and Israel, and leverage our Biopump platform technology as we explore the expansion of our development portfolio into new indications.”

For the past 16 years Dr. Garovoy has been a biotechnology and pharmaceutical industry executive and consultant, having held a variety of positions including Chief Medical Officer at drug development companies working on biologics and small molecule drugs. He has led or been involved with the clinical development and U.S. Food and Drug Administration (FDA) submissions and approvals at a number of companies including Genentech, Inc., XOMA Corporation, Hyperion Therapeutics, Inc, Arriva Pharmaceuticals, Inc,, Peregrine Pharmaceuticals, Inc. and BioMarin Pharmaceutical Inc. He was lead physician on the development of an anti-adhesion monoclonal antibody (Raptiva) in Phase I and Phase II clinical studies at XOMA and in collaboration with Genentech on Phase III clinical studies to FDA approval.

Dr. Garovoy has particular expertise in inflammatory and immunologically mediated diseases including nephrology (kidney transplantation), cardiovascular (heart transplantation), respiratory (asthma, lung transplantation), endocrinology (diabetes), gastrointestinal (inflammatory bowel disease), dermatology (psoriasis, atopic dermatitis), rheumatology (rheumatoid arthritis, systemic lupus) and metabolic diseases.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community


DOW 17,718.96 -38.95 -0.22%
S&P 500 2,073.06 -4.36 -0.21%
NASDAQ 4,999.0930 -14.03 -0.28%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs